Bipartisan issue; outstanding nurses; strategic plan event; financial toxicity
Latest News
April 17, 2025
Bioethics Chats: I. Glenn Cohen "Interest in psychedelics is bipartisan"
Cohen, a Hastings Center Fellow, is the James A. Atwood and Leslie Williams Professor of Law; Deputy Dean of Harvard Law School; and Faculty Director of the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics at Harvard. Last year, he became an elected member of the National Academy of Medicine. He talked with Vardit Ravitsky about his most recent research on the ethical use of psychedelics and some surprising things he’s learned, including that interest in psychedelics is bipartisan. He also shared what he does for fun. (Spoiler alert: who knew law professors play video games!) Read the chat and watch a clip.
2025 Hastings Center Cunniff-Dixon Nursing Awards Announced Nurses commended for exceptional work in hospice and palliative care
Three outstanding nurses have been named the recipients of the 2025 Hastings Center Cunniff-Dixon Nursing Awards, which honor nurses who demonstrate extraordinary compassion and skill in caring for patients nearing the end of life. Read more.
Health Workforce Equity Summit Examining structures and processes for improving trust in health organizations: April 30
Studies show a steady decline in health workers' trust in organizations, and this decline is significantly associated with a reduction in patient trust in clinicians. This summit, cosponsored by The Hastings Center and featuring research scholar Carolyn Neuhaus, will examine the problem and present a series of case studies that may hold promise for rebuilding health workers' trust and, by extension, patient trust. The event will take place at George Washington University. Learn more and register.
The Hastings Center Vision: A Path Forward for Bioethics Join us next week in New York City for the launch of our 2025-2029 strategic plan
There’s still time to register, but space is limited for this special event: our Daniel Callahan Annual Lecture, entitled “The Hastings Center Vision: A Path Forward for Bioethics,” with Hastings Center President Vardit Ravitsky; Joshua Boger, Founder and CEO (former) of Vertex Pharmaceuticals; and Gina Kolata, New York Timeshealth and science reporter. April 24, Rockefeller University: reception: 4:30-5:30 p.m., program: 5:30-7:00 p.m. Reception and lecture are free, but registration is required. Learn more and register.
Financial Toxicity Identified in Cancer Trials Article highlights "hidden costs" of participating in early studies
Among the many burdens cancer patients face is financial toxicity, the high out-of-pocket costs of medical treatment and resulting financial burdens and medical debt. Little known, however, is the financial toxicity to patients who volunteer for early-phase cancer clinical trials – increased costs of travel and other expenses, and the negative impact these financial burdens can have on research participants’ health outcomes and quality of life. An article in Ethics & Human Research argues that researchers should tell prospective participants about the risk of financial toxicity to “demonstrate that they respect their patients’ autonomy, seek to protect them from preventable harm, and ensure the participants’ well-being takes precedence over the needs of the research.” Read more. (Subscription required for full text.)
The Hastings Center Vision: A Path Forward for Bioethics, the launch of The Hastings Center's strategic plan at our Daniel Callahan Annual Lecture, with Vardit Ravitsky, Joshua Boger, and Gina Kolata. New York City, April 24.
AI in Healthcare: Trust and Accountability. Conference jointly presented by Cedars-Sinai and The Hastings Center. Los Angeles, May 16.
The Hastings Center seeks to ensure responsible health and science policy and practice. We work to secure the wisest possible use of emerging technologies and fair, compassionate, and just health care for people across their lifespan.
We strongly value your privacy and would never sell, give, or otherwise share your information. Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
